Literature DB >> 24467232

Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.

David R Barnidge1, Surendra Dasari, Chad M Botz, Danelle H Murray, Melissa R Snyder, Jerry A Katzmann, Angela Dispenzieri, David L Murray.   

Abstract

A monoclonal gammopathy is defined by the detection a monoclonal immunoglobulin (M-protein). In clinical practice, the M-protein is detected by protein gel electrophoresis (PEL) and immunofixation electrophoresis (IFE). We theorized that molecular mass could be used instead of electrophoretic patterns to identify and quantify the M-protein because each light and heavy chain has a unique amino acid sequence and thus a unique molecular mass whose increased concentration could be distinguished from the normal polyclonal background. In addition, we surmised that top-down MS could be used to isotype the M-protein because each immunoglobulin has a constant region with an amino acid sequence unique to each isotype. Our method first enriches serum for immunoglobulins followed by reduction using DTT to separate light chains from heavy chains and then by microflow LC-ESI-Q-TOF MS. The multiply charged light and heavy chain ions are converted to their molecular masses, and reconstructed peak area calculations for light chains are used for quantification. Using this method, we demonstrate how the light chain portion of an M-protein can be monitored by molecular mass, and we also show that in sequential samples from a patient with multiple myeloma the light chain portion of the M-protein was detected in all samples, even those negative by PEL, IFE, and quantitative FLC. We also present top-down MS isotyping of M-protein light chains using a unique isotype-specific fragmentation pattern allowing for quantification and isotype identification in the same run. Our results show that microLC-ESI-Q-TOF MS provides superior sensitivity and specificity compared to conventional methods and shows promise as a viable method of detecting and isotyping an M-protein.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24467232     DOI: 10.1021/pr400985k

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  32 in total

1.  Bioinformatics Analysis of Top-Down Mass Spectrometry Data with ProSight Lite.

Authors:  Caroline J DeHart; Ryan T Fellers; Luca Fornelli; Neil L Kelleher; Paul M Thomas
Journal:  Methods Mol Biol       Date:  2017

Review 2.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

3.  Pseudo-monoclonal gammopathy: a report of four cases.

Authors:  Majd D Jawad; Ronald S Go; Thomas E Witzig; Joseph R Mikhael; Aishwarya Ravindran; David L Murrray
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

4.  Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry.

Authors:  Paula M Ladwig; David R Barnidge; Maria A V Willrich
Journal:  J Am Soc Mass Spectrom       Date:  2016-12-21       Impact factor: 3.109

Review 5.  Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Authors:  Shalin Kothari; Jens Hillengass; Philip L McCarthy; Sarah A Holstein
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

6.  Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

Authors:  Marion Eveillard; Even Rustad; Mikhail Roshal; Yanming Zhang; Amanda Ciardiello; Neha Korde; Malin Hultcrantz; Sydney Lu; Urvi Shah; Hani Hassoun; Eric Smith; Alexander Lesokhin; Sham Mailankody; Ola Landgren; Katie Thoren
Journal:  Br J Haematol       Date:  2020-02-05       Impact factor: 6.998

7.  Deep and quantitative top-down proteomics in clinical and translational research.

Authors:  Neil L Kelleher; Paul M Thomas; Ioanna Ntai; Philip D Compton; Richard D LeDuc
Journal:  Expert Rev Proteomics       Date:  2014-10-28       Impact factor: 3.940

8.  Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Authors:  Kazunori Murata; Samuel I McCash; Brittany Carroll; Alexander M Lesokhin; Hani Hassoun; Nikoletta Lendvai; Neha S Korde; Sham Mailankody; Heather J Landau; Guenther Koehne; David J Chung; Sergio A Giralt; Lakshmi V Ramanathan; Ola Landgren
Journal:  Clin Biochem       Date:  2016-09-21       Impact factor: 3.281

9.  Immunoglobulins: expanding the role for mass spectrometry in protein biomarker quantification.

Authors:  John M Koomen
Journal:  Clin Chem       Date:  2014-06-17       Impact factor: 8.327

10.  Comparative top down proteomics of peripheral blood mononuclear cells from kidney transplant recipients with normal kidney biopsies or acute rejection.

Authors:  John P Savaryn; Timothy K Toby; Adam D Catherman; Ryan T Fellers; Richard D LeDuc; Paul M Thomas; John J Friedewald; Daniel R Salomon; Michael M Abecassis; Neil L Kelleher
Journal:  Proteomics       Date:  2016-07       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.